Published in
Esmo Open, Esmo Open, 3(6), p. 100137, 2021
DOI: 10.1016/j.esmoop.2021.100137
Links
Tools
Corrigendum to ‘The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer’
Journal article published in 2021 by
This paper was not found in any repository; the policy of its publisher is unknown or unclear.
Full text: Unavailable
Data provided by 